These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

609 related articles for article (PubMed ID: 17892849)

  • 1. Human immunodeficiency virus controllers: mechanisms of durable virus control in the absence of antiretroviral therapy.
    Deeks SG; Walker BD
    Immunity; 2007 Sep; 27(3):406-16. PubMed ID: 17892849
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human immunodeficiency virus pathogenesis and prospects for immune control in patients with established infection.
    Cohen DE; Walker BD
    Clin Infect Dis; 2001 Jun; 32(12):1756-68. PubMed ID: 11360218
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathogenic insights from studies of lymphoid tissue from HIV-infected individuals.
    Cohen OJ; Pantaleo G; Schwartzentruber DJ; Graziosi C; Vaccarezza M; Fauci AS
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 1():S6-14. PubMed ID: 8595512
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Soluble factors with inhibitory activity against type 1 Human Immunodeficiency Virus].
    Zapata W; Montoya CJ; Rugeles MT
    Biomedica; 2006 Sep; 26(3):451-66. PubMed ID: 17176009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
    Panel de expertos de Gesida y Plan Nacional sobre el Sida
    Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune-based approaches for control of HIV infection and viral-induced immunopathogenesis.
    Pinto LA; Shearer GM; Blazevic V
    Clin Immunol; 2000 Oct; 97(1):1-8. PubMed ID: 10998312
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular and cellular interactions of HIV-1/HTLV coinfection and impact on AIDS progression.
    Casoli C; Pilotti E; Bertazzoni U
    AIDS Rev; 2007; 9(3):140-9. PubMed ID: 17982939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune restoration disease in HIV patients: aberrant immune responses after antiretroviral therapy.
    French M; Price P
    J HIV Ther; 2002 May; 7(2):46-51. PubMed ID: 12553688
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.
    Steingrover R; Pogány K; Fernandez Garcia E; Jurriaans S; Brinkman K; Schuitemaker H; Miedema F; Lange JM; Prins JM
    AIDS; 2008 Aug; 22(13):1583-8. PubMed ID: 18670217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suppression of viral replication with highly active antiretroviral therapy has no impact on the functional profile of HIV-specific CD8(+) T cells.
    López M; Soriano V; Rallón N; Cascajero A; González-Lahoz J; Benito JM
    Eur J Immunol; 2008 Jun; 38(6):1548-58. PubMed ID: 18421792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Delayed early antiretroviral treatment is associated with an HIV-specific long-term cellular response in HIV-1 vertically infected infants.
    Palma P; Romiti ML; Cancrini C; Pensieroso S; Montesano C; Bernardi S; Amicosante M; Di Cesare S; Castelli-Gattinara G; Wahren B; Rossi P
    Vaccine; 2008 Sep; 26(40):5196-201. PubMed ID: 18471944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Host genetic factors that control immune responses to retrovirus infections.
    Miyazawa M; Tsuji-Kawahara S; Kanari Y
    Vaccine; 2008 Jun; 26(24):2981-96. PubMed ID: 18255203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-HIV adaptive immunity: determinants for viral persistence.
    Yamamoto H; Matano T
    Rev Med Virol; 2008; 18(5):293-303. PubMed ID: 18416450
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recovery of viremic control after superinfection with pathogenic HIV type 1 in a long-term elite controller of HIV type 1 infection.
    Rachinger A; Navis M; van Assen S; Groeneveld PH; Schuitemaker H
    Clin Infect Dis; 2008 Dec; 47(11):e86-9. PubMed ID: 18947331
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment research priorities for human immunodeficiency virus infection.
    Pettinelli CB; Schnittman SM
    Infect Agents Dis; 1993 Oct; 2(5):291-303. PubMed ID: 8173814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune activation and antibody responses in non-progressing elite controller individuals infected with HIV-1.
    Bello G; Velasco-de-Castro CA; Bongertz V; Rodrigues CA; Giacoia-Gripp CB; Pilotto JH; Grinsztejn B; Veloso VG; Morgado MG
    J Med Virol; 2009 Oct; 81(10):1681-90. PubMed ID: 19697415
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms involved in non-progressive HIV disease.
    Mikhail M; Wang B; Saksena NK
    AIDS Rev; 2003; 5(4):230-44. PubMed ID: 15012002
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tight regulation of the Epstein-Barr virus setpoint: interindividual differences in Epstein-Barr virus DNA load are conserved after HIV infection.
    Piriou E; van Dort K; Otto S; van Oers MH; van Baarle D
    Clin Infect Dis; 2008 Jan; 46(2):313-6. PubMed ID: 18171268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Notes on the pathogenesis of human immunodeficiency virus infection.
    Piconi S; Clerici M
    Ann Ist Super Sanita; 1997; 33(2):219-23. PubMed ID: 9470244
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Investigation of anti-R7V antibodies in HIV-infected patients under highly active antiretroviral therapy].
    Ergünay K; Altinbaş A; Calik Başaran N; Unal S; Us D; Karabulut E; Ustaçelebi S
    Mikrobiyol Bul; 2008 Jul; 42(3):413-9. PubMed ID: 18822884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.